EXHIBIT 10.15=============================================================================== ASSET PURCHASE AGREEMENT dated as of April 10, 2006 by and between ABBOTT LABORATORIES (“Seller”) and IMARX THERAPEUTICS, INC. (“Buyer”)=============================================================================== TABLE OF CONTENTS PAGE —-ARTICLE 1 DEFINITIONS……………………………………………. 1 1.1 Definitions…………………………………………… 1ARTICLE 2 PURCHASE AND SALE………………………………………. 4 2.1 Agreements to Purchase and Sell…………………………. 4 2.2 Excluded Assets……………………………………….. 5 2.3 Assumed Liabilities……………………………………. 7 2.4 Excluded Liabilities…………………………………… 7 2.5 Procedures for Purchased Assets not Transferable………….. 8ARTICLE 3 PURCHASE PRICE; CONSISTENT TREATMENT……………………… 9 3.1 Purchase Price………………………………………… 9 3.2 Payment of Purchase Price………………………………. 9 3.3 Purchase Price Allocation………………………………. 9 3.4 Prorations……………………………………………. 9ARTICLE 4 CLOSING……………………………………………….. 9 4.1 Closing Date………………………………………….. 9 4.2 Transactions at Closing………………………………… 9ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF SELLER………………….. 10 5.1 Organization………………………………………….. 10 5.2 Due Authorization……………………………………… 10 5.3 Inventory, Equipment and Raw Materials…………………… 11 5.4 Title………………………………………………… 11 5.5 Intellectual Property………………………………….. 11 5.6 Litigation……………………………………………. 11 5.7 Consents……………………………………………… 12 5.8 Brokers, Etc………………………………………….. 12 5.9 Financial Information………………………………….. 12 5.10 Absence of Undisclosed Liabilities………………………. 12 5.11 Absence of Unusual Changes and Unusual Transactions……….. 12 5.12 Governmental Authorizations…………………………….. 12 5.13 Contracts…………………………………………….. 12 5.14 Tax Matters…………………………………………… 13 5.15 Cell Banks……………………………………………. 13 5.16 Disclaimer……………………………………………. 13ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF BUYER…………………… 14 6.1 Organization………………………………………….. 14 6.2 Due Authorization……………………………………… 14 6.3 Consents……………………………………………… 14 6.4 Litigation……………………………………………. 14 6.5 Breach of Representations and Warranties…………………. 14 6.6 Brokers, Etc………………………………………….. 14 6.7 Independent Investigation………………………………. 15 6.8 Indebtedness………………………………………….. 15 i TABLE OF CONTENTS PAGE —-ARTICLE 7 PRE-CLOSING COVENANTS OF SELLER AND BUYER…………………. 15 7.1 Corporate and Other Actions…………………………….. 15 7.2 Consents and Approvals…………………………………. 15 7.3 Competition Law Filings………………………………… 15 7.4 Access to Information………………………………….. 16 7.5 Ordinary Course of Business…………………………….. 16ARTICLE 8 CONDITIONS…………………………………………….. 16 8.1 Conditions to Obligations of Seller……………………… 16 8.2 Conditions to Obligations of Buyer………………………. 17ARTICLE 9 POST-CLOSING COVENANTS, OTHER AGREEMENTS………………….. 18 9.1 Assumed Liabilities……………………………………. 18 9.2 Availability of Records………………………………… 18 9.3 Use of Trade or Service Marks…………………………… 19 9.4 Tax Matters…………………………………………… 19 9.5 Chargebacks…………………………………………… 20 9.6 Non-competition by Seller………………………………. 20 9.7 Regulatory Transfer……………………………………. 20 9.8 Post-Closing Delivery………………………………….. 20 9.9 Transition Services……………………………………. 20 9.10 No Other Compensation………………………………….. 21ARTICLE 10 INDEMNIFICATION AND SURVIVAL……………………………. 21 10.1 Indemnification by Seller………………………………. 21 10.2 Indemnification by Buyer……………………………….. 22 10.3 Survival……………………………………………… 23 10.4 Exclusive Remedy………………………………………. 24 10.5 Net Losses and Subrogation……………………………… 24 10.6 Insurance…………………………………………….. 24ARTICLE 11 TERMINATION…………………………………………… 25 11.1 Termination of Agreement……………………………….. 25 11.2 Automatic Termination………………………………….. 25 11.3 Continuing Effectiveness……………………………….. 25ARTICLE 12 MISCELLANEOUS…………………………………………. 25 12.1 Assignment……………………………………………. 25 12.2 No Press Release Without Consent………………………… 25 12.3 Confidentiality……………………………………….. 26 12.4 Expenses……………………………………………… 26 12.5 Severability………………………………………….. 26 12.6 Entire Agreement………………………………………. 26 12.7 No Third Party Beneficiaries……………………………. 27 12.8 Waiver……………………………………………….. 27 12.9 Governing Law…………………………………………. 27 12.10 Headings……………………………………………… 27 12.11 Counterparts………………………………………….. 27 ii TABLE OF CONTENTS PAGE —- 12.12 Further Documents……………………………………… 27 12.13 Notices………………………………………………. 27 12.14 Schedules…………………………………………….. 28 12.15 Construction………………………………………….. 29 iii EXHIBITS AND SCHEDULESEXHIBITSExhibit A – Assignment and Assumption AgreementExhibit B – Intellectual Property Transfer AgreementExhibit C – Inventory Trademark License AgreementExhibit D – Promissory NoteExhibit E – Security AgreementExhibit F – Escrow AgreementExhibit G – Testing ProceduresSCHEDULESSchedule 1.1 – Knowledge PersonsSchedule 2.1(b) – Transferred Intellectual PropertySchedule 2.1(c) – Cell BanksSchedule 2.1(d)(i) – ContractsSchedule 2.1(f) – Seller Labeled InventorySchedule 2.1(g) – Sales MaterialsSchedule 2.1(h) – Product ApplicationsSchedule 2.1(j) – Stock in TradeSchedule 2.1(k) – Raw MaterialsSchedule 2.5 – Mixed GPO ContractsSchedule 5.4 – TitleSchedule 5.5 – Intellectual PropertySchedule 5.6 – LitigationSchedule 5.7 – Seller ConsentsSchedule 5.9 – Financial DataSchedule 5.12 – Governmental AuthorizationsSchedule 6.3 – Buyer ConsentsSchedule 6.8 – Indebtedness iv ASSET PURCHASE AGREEMENT THIS AGREEMENT, dated as of April 10, 2006 is entered into by and betweenABBOTT LABORATORIES, an Illinois corporation (“Seller”), and IMARX THERAPEUTICS,INC., a Delaware corporation (“Buyer”). WHEREAS, Seller wishes to sell to Buyer the Purchased Assets and AssumedLiabilities (each as defined below), and Buyer wishes to purchase such assetsfrom Seller and to assume such liabilities. NOW, THEREFORE, in consideration of the premises and mutual covenants,agreements and provisions herein contained, the parties hereto agree as follows: ARTICLE 1 Definitions 1.1 Definitions. The following terms have the following meanings when usedherein: “$” means United States dollars. “Affiliate” means, with respect to any Person, any other Person directlyor indirectly controlling or controlled by, or under direct or indirect commoncontrol with, such Person. For purposes of this definition, a Person shall bedeemed to control another Person if it owns or controls more than fifty percent(50%) of the voting equity of the other Person (or other comparable ownership ifthe Person is not a corporation). For purposes of clarification, with respect toSeller, the term “Affiliate” shall specifically exclude TAP Holdings Inc., TAPFinance Inc. and TAP Pharmaceuticals Products Inc. “Agreement” means this Asset Purchase Agreement, including all Schedulesand Exhibits hereto, as it may be amended from time to time in accordance withits terms. “Allocation Schedule” has the meaning set forth in Section 3.3. “Annual Report” means an annual report filed by Seller with the FDArelating to the Product. “Assignment and Assumption Agreement” means the Assignment and AssumptionAgreement and Bill of Sale in substantially the form attached hereto as ExhibitA. “Assumed Liabilities” has the meaning set forth in Section 2.3. “Buyer” has the meaning set forth in the recitals hereof. “Cell Banks” has the meaning set forth in Section 2.1(c). “Chargeback” means all credits, chargebacks, rebates, reimbursements,administrative fees, and other amounts owed to wholesalers, distributors, grouppurchasing organizations,insurers, and other institutions pursuant to any Contract. “Seller Chargeback”means Chargebacks arising out of Products sold to customers prior to the Closingand “Buyer Chargeback” means Chargebacks arising out of transactions consummatedon or after the Closing. “Closing” means the closing of the purchase and sale of the PurchasedAssets and assumption of the Assumed Liabilities contemplated by this Agreement. “Closing Date” means April 28, 2006, or such other date as may be mutuallyagreed upon by the Buyer and Seller. “Confidential Information” has the meaning set forth in Section 12.3. “Contracts” has the meaning set forth in Section 2.1(d). “Disclosure Schedules” shall mean those schedules attached hereto. “Encumbrance” means any encumbrance, lien, charge, pledge, mortgage, titleretention agreement, security interest of any nature, adverse claim, exception,reservation, easement, right of occupation, any matter capable of registrationagainst title, option, right of pre-emption or privilege or any agreement orother commitment, whether written or oral, to create any of the foregoing. “Escrow Agreement” means the Escrow Agreement in substantially the formattached hereto as Exhibit F. “Excluded Assets” has the meaning set out in Section 2.2. “Excluded Liabilities” has the meaning set forth in Section 2.4. “FDA” means the U.S. Food and Drug Administration. “GAAP” means United States generally accepted accounting principlesconsistently applied from period to period and throughout any period inaccordance with the past practices of Seller or Buyer, as the case may be. “Governmental Authorizations” has the meaning set forth in Section 2.1(e). “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976,as amended. “Indemnified Person” has the meaning set forth in Section 10.5(a). “Indemnifying Person” has the meaning set forth in Section 10.5(a). “Intellectual Property Rights” means all intellectual property, industrialand other proprietary rights, protected or protectable, under the laws of theUnited States or any other country, or any political subdivision thereof,including, without limitation, (i) all trade names, trade dress, trademarks,service marks, logos, brand names and other identifiers; (ii) copyrights, 2moral rights (including rights of attribution and rights of integrity); (iii)all trade secrets, inventions, discoveries, devices, processes, designs,techniques, trade secrets, ideas, know-how and other confidential or proprietaryinformation, whether or not reduced to practice; (iv) all domestic and foreignpatents and the registrations, applications, renewals, extensions, divisionalsand continuations (in whole or in part) thereof; and (v) all goodwill associatedtherewith and all rights and causes of action for infringement,misappropriation, misuse, dilution or unfair trade practices associated with (i)through (iv) above. “Intellectual Property Transfer Agreement” means the Intellectual PropertyTransfer Agreement in substantially the form attached hereto as Exhibit B. “Inventory” has the meaning set forth in Section 2.1(f). “Inventory Trademark License Agreement” means the Inventory TrademarkLicense Agreement in substantially the form attached hereto as Exhibit C. “Knowledge” means, with respect to Seller, the actual knowledge afterreasonable inquiry of the persons listed on Schedule 1.1. “Losses” has the meaning set forth in Section 10.1(a). “Master Cell Bank” means Cell Suspension of Urokinase Kidney Cells, Code81987, as described on Schedule 2.1(c). “Mixed GPO Contracts” means those Group Purchasing Organization contracts(including related contracts entered into in connection therewith) relating toboth Purchased Assets and other products of Seller listed on Schedule2.1(d)(ii). “New GPO Contract” has the meaning set forth in Section 2.5(b). “NDA 76-1021” means new drug application 76-1021 filed with the FDA,subsequently assigned the new NDA 21-846. “Other Agreements” means, collectively, the Assignment and AssumptionAgreement, the Intellectual Property Transfer Agreement, the Inventory TrademarkLicense Agreement, the Promissory Note, the Security Agreement and the EscrowAgreement. “Person” means any individual, corporation, partnership, limitedpartnership, joint venture, limited liability company, trust or unincorporatedorganization or government or any agency or political subdivision thereof. “Product” or “Products” means Seller’s urokinase product marketed underthe brand Abbokinase(R). “Promissory Note” has the meaning set forth in Section 3.1(b). “Purchase Price” has the meaning set forth in Section 3.1. 3 “Purchased Assets” has the meaning set forth in Section 2.1. “Raw Materials” means those raw materials set forth on Schedule 2.1(k). “Security Agreement” means the Security Agreement in substantially theform attached hereto as Exhibit E. “Seller” has the meaning set forth in the recitals hereof. “SNDAs” means supplemental new drug applications S-076 through S-095 andthe supplemental application for CBE-30 filed with the FDA. “Stock in Trade” has the meaning set forth in Section 2.1(j). “Taxes” shall mean all taxes, charges, fees, duties, levies or otherassessments, including, without limitation, income, gross receipts, netproceeds, ad valorem, turnover, real and personal property (tangible andintangible), sales, use, franchise, excise, value added, goods and services,license, payroll, unemployment, environmental, customs duties, capital stock,disability, stamp, leasing, lease, user, transfer, fuel, excess profits,occupational and interest equalization, windfall profits, severance andemployees’ income withholding and social security and similar employment taxesimposed by the United States or any other foreign country or by any state,municipality, subdivision or instrumentality of the Unites States or of anyother foreign country or by any other tax authority, including all applicablepenalties and interest, and such term shall include any interest, penalties oradditions to tax attributable to such taxes. “Testing Procedures” means the procedures set forth on Exhibit G hereto. “Thrombolytic Therapy Product” means serine proteases that convertplasminogen to plasmin to break down the fibrinogen and fibrin to dissolve athrombus in an artery, vein or in-dwelling catheter, or any proteases orprotease activators which catalyze proteolytic breakdown of fibrinogen or fibrinfor the same purpose. “Transferred Intellectual Property” has the meaning set forth in Section2.1(b). “United States” means the United States of America. “Working Cell Banks” means Cell Suspension Subcultured from UrokinaseKidney Cells, Frozen Sub-2, Code 48647 as Schedule 2.1(c). ARTICLE 2 Purchase and Sale 2.1 Agreements to Purchase and Sell. Subject to the terms and conditionscontained herein, at the Closing Seller shall sell, transfer, convey, assign anddeliver to Buyer, and Buyer shall purchase and accept from Seller, all right,title, and interest of Seller in and to the following assets of Seller(collectively, the “Purchased Assets”): 4 (a) all sales and marketing information, including all customerlists of Seller, relating primarily to the Products; (b) (i) the trademarks, patents, and patent applications set forthon Schedule 2.1(b), (ii) the package designs, labels, logos and associatedartwork primarily related to the Products and (iii) all technical information,references and standards, methodologies, processes, protocols, specifications,techniques, trade secrets and know how, databases and formulas primarily relatedto the Products and any supporting documentation that relates primarily to theProducts (collectively, the “Transferred Intellectual Property”); (c) the Master Cell Bank and Working Cell Banks described onSchedule 2.1(c) (the “Cell Banks”); (d) all rights and interest of Seller to the contracts relating tothe Products set forth on Schedule 2.1(d)(i) (the “Contracts”); (e) all licenses, approvals, certificates, permits, franchises, orother evidence of authority issued to Seller or Seller’s Affiliates by afederal, state, local or foreign governmental agency or authority, regardless ofjurisdiction, relating primarily to the Products, in each case to the extentassignable, including NDA 76-1021 and the SNDAs (the “GovernmentalAuthorizations”); (f) 153,000 vials of unlabelled Product that have been approved bySeller for distribution, but have not been approved by the FDA (“Inventory”); (g) all records, reports, Product information files (includingProduct development and regulatory history files) and sales, advertising andmarketing information files of Seller and Seller’s Affiliates, in each caserelating primarily to the Products, including without limitation the itemsidentified on Schedule 2.1(g); (h) all current and pending new drug applications for the Productsas set forth on Schedule 2.1(h); (i) all goodwill relating exclusively to the Products; (j) any Stock-in-Trade described on Schedule 2.1(j); and (k) the Raw Materials. 2.2 Excluded Assets. Notwithstanding anything to the contrary in thisAgreement, Seller shall not sell, transfer or assign, and Buyer shall notpurchase or otherwise acquire, the following assets of Seller (such assets beingcollectively referred to hereinafter as the “Excluded Assets”): (a) all rights of Seller and Seller’s Affiliates arising under this Agreement, the Other Agreements or from the consummation of the transactions contemplated hereby or thereby; 5 (b) all accounts receivable, notes receivable, cash, bank deposits, marketable securities and intercompany receivable balances owed to Seller or Seller’s Affiliates with respect to the Products existing at the Closing Date; (c) all rights of Seller and Seller’s Affiliates arising under any contract other than the Contracts; (d) all corporate minute books, stock records and Tax returns (including all work papers relating to such Tax returns) of Seller and Seller’s Affiliates and such other similar corporate books and records of Seller and Seller’s Affiliates as may exist on the Closing Date; (e) all real property, buildings, structures and improvements thereon, whether owned or leased by Seller or Seller’s Affiliates, and all fixtures and fittings attached thereto, including those in the buildings designated by Seller as the M3, M3B, M6 and M10 buildings in its North Chicago, Illinois location; (f) all Intellectual Property Rights of Seller or Seller’s Affiliates of any kind not listed on Schedule 2.1(b) or referred to in Section 2.1(d), specifically including the trademarks or trade names “Abbott,” “Abbott Laboratories” and any variants thereof, the stylized symbol “A,” the Abbokinase OpenCath(R) trademark and the ABBOKINASE(R) trademark, which is the subject of the Inventory Trademark License Agreement; (g) all rights to refunds of Taxes paid by or on behalf of Seller or Seller’s Affiliates; (h) all insurance policies and claims thereunder existing at the Closing Date; (i) all Seller and Seller Affiliate intercompany payable balances relating to the Products; (j) the services of any employee of Seller or Seller’s Affiliates; (k) all assets of any employee benefit plan, arrangement, or program maintained or contributed to by Seller or any of its Affiliates; (l) all assets, tangible or intangible, wherever situated, not expressly included in the Purchased Assets; (m) all raw materials not listed in Schedule 2.1(k); and (n) all equipment of Seller or Seller’s Affiliates. 6 2.3 Assumed Liabilities. On the Closing Date, subject to the provisions ofSection 2.4, Buyer shall assume, or shall cause Buyer’s Affiliates to assume,the following liabilities of Seller and Seller’s Affiliates relating primarilyto the Purchased Assets existing on the Closing Date as follows (collectively,together with all other obligations and liabilities of Seller and Seller’sAffiliates assumed by Buyer or Buyer’s Affiliates pursuant to this Agreement andthe Schedules hereto, the “Assumed Liabilities”): (a) all liabilities and all obligations arising after the Closing Date under the Contracts, the Transferred Intellectual Property and the Governmental Authorizations being transferred from Seller to Buyer hereunder; (b) Taxes that are the responsibility of Buyer pursuant to Section 3.4, Section 9.4(a) and Section 12.4 of this Agreement and all Taxes related to Products and Purchased Assets attributable to any period or partial period ending after the Closing; (c) Except as provided in Section 2.4(f), all liabilities or other claims related to the research, development, marketing, manufacture, distribution, testing, sale or trials of the Products that arise after the Closing Date. 2.4 Excluded Liabilities. Neither Buyer nor Buyer’s Affiliates assume norwill they become responsible for any of the liabilities and obligations ofSeller or Seller’s Affiliates (collectively, the “Excluded Liabilities”) exceptfor those set out in Section 2.3. The Excluded Liabilities shall include,without limitation: (a) all liabilities and obligations of Seller and Seller’s Affiliates arising under this Agreement, the Other Agreements or from the consummation of the transactions contemplated hereby or thereby; (b) all intercompany payable balances owing to Seller or Seller’s Affiliates; (c) all liabilities and obligations of Seller and Seller’s Affiliates arising under any contract or agreement not set forth on Schedule 2.1(c); (d) all obligations related to employees of Seller or Seller’s Affiliates; (e) any and all claims, causes of action or litigation to the extent relating to Products sold prior to the Closing, including the matters set forth on Schedule 5.6; (f) any and all claims, causes of action or litigation relating to Products sold after Closing to the extent related to Seller’s failure to manufacture the Inventory in compliance with the standards set forth in the specifications in the SNDAs; and (g) other current liabilities (except Assumed Liabilities) of Seller or Seller’s Affiliates incurred in the ordinary course of business and existing at the Closing Date. 72.5 Procedures for Purchased Assets not Transferable. If any of the Contracts orany other property or rights included in the Purchased Assets are not assignableor transferable either by virtue of the provisions thereof or under applicablelaw without the consent of some party or parties, Seller shall use itscommercially reasonable efforts to obtain such consents after the execution ofthis Agreement, but prior to the Closing, and Buyer shall use its commerciallyreasonable efforts to assist in that endeavor. If any such consent cannot beobtained prior to the Closing and the Closing occurs, this Agreement and therelated instruments of transfer shall not constitute an assignment or transferthereof and Buyer shall not assume Seller’s obligations with respect thereto,but Seller shall use its commercially reasonable efforts to obtain such consentas soon as reasonably possible after the Closing or otherwise obtain for Buyerthe practical benefit of such property or rights and Buyer shall use itscommercially reasonable efforts to assist in that endeavor. For purposes of thisSection 2.5, commercially reasonable efforts shall not include any requirementof either party to expend money, commence any litigation or offer or grant anyaccommodation (financial or otherwise) to any third party. In the case of anyContracts for which a necessary consent has not been obtained, Buyer shallprovide all goods and services and bear all costs necessary to complete suchContracts at no cost to Seller, and Seller shall hold for Buyer’s account andpromptly remit to Buyer all amounts received with respect to such Contracts. (b) The parties shall use their commercially reasonable efforts to causethe purchaser under each of the Mixed GPO Contracts to enter into a newagreement or amendment with Buyer or to assign the Agreement to Buyer pursuantto which the provisions of the Mixed GPO Contracts relating to future sales ofProducts shall be terminated and replaced by such new agreement, amendment orassignment between the purchaser and Buyer on substantially similar terms as theapplicable Mixed GPO Contract (“New GPO Contract”). (c) In the event that Buyer has not, despite its commercially reasonableefforts, entered into a New GPO Contract with respect to each of the top five(5) Mixed GPO Contracts identified on Schedule 2.5 within one hundred twenty(120) days following Closing (the “Final GPO Date”), Buyer shall be entitled toa credit against the Promissory Note equal to one hundred thousand dollars($100,000) multiplied by the number of such top five Mixed GPO Contracts forwhich no New GPO Contract exists as of such date. (d) On the Final GPO Date, the principal balance of the Promissory Note asof the Final GPO Date shall be reduced by an amount equal to one hundredthousand dollars multiplied by the number of top five Mixed GPO Contracts notreplaced with New GPO Contracts prior to the Final GPO Date. 8 ARTICLE 3 Purchase Price; Consistent Treatment 3.1 Purchase Price. The purchase price (“Purchase Price”) for thePurchased Assets shall consist of (a) a payment at Closing in the amount of FiveMillion U.S. dollars ($5.0 million), plus the assumption of the AssumedLiabilities and (b) a promissory note in substantially the form attached heretoas Exhibit D in the principal amount of Fifteen Million U.S. dollars (the”Promissory Note”). 3.2 Payment of Purchase Price. The Purchase Price shall be paid inaccordance with Section 4.2(b). 3.3 Purchase Price Allocation. The Purchase Price shall be allocated amongthe Purchased Assets as set forth in a schedule (the “Allocation Schedule”) thatBuyer will prepare and deliver to Seller on or before the Closing Date, whichallocation shall be subject to the reasonable approval of Seller. Each of Sellerand Buyer shall sign and submit all necessary forms to report this transactionfor federal, state and foreign income tax purposes in accordance with theAllocation Schedule, and shall not take a position for Tax purposes inconsistenttherewith. Any adjustment to the Purchase Price shall be allocated as providedby Treasury Regulation Section 1.1060-1. 3.4 Prorations. Seller and Buyer agree that all of the items listed belowrelating to the Purchased Assets will be prorated as of the Closing Date, withSeller liable to the extent such items relate to any time period up to andincluding the Closing Date and Buyer liable to the extent such items relate toperiods subsequent to the Closing Date: (a) personal property Taxes, if any,attributable to the Purchased Assets; (b) rents, Taxes and other items payableby Seller under any lease, contract to be assigned to or assumed by Buyerhereunder or for which Buyer is entitled to enjoy the practical benefitspursuant to Section 2.5; (c) the amount of any license or registration fees withrespect to any licenses or registrations which are being assigned or transferredhereunder; and (d) all other items which are normally prorated in connectionwith similar transactions. Seller agrees to furnish Buyer with such documentsand other records as Buyer reasonably requests in order to confirm alladjustment and proration calculations made pursuant to this Section 3.4. ARTICLE 4 Closing 4.1 Closing Date. The Closing shall take place at the offices of Kirkland& Ellis LLP, 200 East Randolph Drive, Chicago, Illinois 60601, at 10:00 a.m.Chicago time, on the Closing Date subject to the satisfaction or waiver of eachof the conditions set forth in Article 8 or at such other place, time or date asSeller and Buyer may agree. 4.2 Transactions at Closing. At the Closing, subject to the terms andconditions hereof: (a) Transfer of Purchased Assets. Seller shall transfer and convey or cause to be transferred and conveyed to Buyer all of the Purchased Assets and Seller and Buyer shall 9 execute and Seller shall deliver to Buyer the Assignment and Assumption Agreement, each of the Other Agreements and such other good and sufficient instruments of transfer and conveyance as shall be necessary to vest in Buyer title to all of the Purchased Assets. In addition, Seller shall deliver to Buyer the certificate required by Section 8.2(b) and all other documents required to be delivered by Seller at Closing pursuant hereto. (b) Payment of Purchase Price, Assumption of Assumed Liabilities and Buyer’s Closing Deliveries. In consideration for the transfer of the Purchased Assets, Buyer shall: (i) pay to Seller on the Closing Date Five Million ($5,000,000) of the Purchase Price in United States dollars by electronic bank transfer in immediately available funds directly to Seller’s Account No. 00001329 at Citibank, N.A. in New York, New York, ABA #021000089 (Swift Code: CITIUS33); (ii) deliver to Seller the Promissory Note; and (iii) execute and deliver to Seller the Assignment and Assumption Agreement, whereby Buyer assumes the Assumed Liabilities, and each of the Other Agreements, as well as the certificate required by Section 8.1(b) and all other documents required to be delivered by Buyer at Closing pursuant hereto. (c) Regulatory Transfer. At Closing, Seller will provide to Buyer copies of all portions of NDA 76-1021 and the SNDAs necessary to allow Buyer to comply with its obligations as the application holder. Seller further agrees to notify the FDA of the transfer of NDA 76-1021 in accordance with Section 505(j) of the Federal Food, Drug and Cosmetic Act and 21 CFR 314.72. Buyer agrees to notify the FDA of the transfers of NDA 76-1021 and SNDAs effective immediately upon the Closing and to submit as the new owner an application Form FDA 356h. ARTICLE 5 Representations and Warranties of Seller Except as set forth in the Disclosure Schedules, Seller represents andwarrants to Buyer as follows: 5.1 Organization. Seller is a corporation duly incorporated and validlyexisting in good standing under the laws of the State of Illinois, dulyqualified to transact business as a foreign corporation in such jurisdictionswhere the nature of the Purchased Assets makes such qualification necessary,except as to jurisdictions where the failure to qualify would not reasonably beexpected to have a material adverse effect on the Purchased Assets, and with allrequisite corporate power and authority to own, lease and operate the PurchasedAssets and to carry on its business relating to the Purchased Assets as nowbeing conducted. 5.2 Due Authorization. Seller has full corporate power and authority toexecute, deliver and perform its obligations under this Agreement and the OtherAgreements, and the execution and delivery of this Agreement and the OtherAgreements and the performance of all of its obligations hereunder andthereunder have been duly authorized by Seller. The signing, delivery andperformance of this Agreement and the Other Agreements by Seller is notprohibited or limited by, and will not result in the breach of or a defaultunder, or conflict with any obligation of Seller with respect to the PurchasedAssets under (i) any provision of the Articles of 10Incorporation or By-Laws of Seller, (ii) any material agreement or instrument towhich Seller is a party or by which it or its properties are bound, (iii) anyjudgment, order, award, writ, injunction or decree of any court, governmentalbody or instrumentality, or arbitrator, (iv) any Governmental Authorizations, or(v) any applicable law, statute, ordinance, regulation or rule, and, to Seller’sKnowledge, will not result in the creation or imposition of any Encumbrance onany of the Purchased Assets, except to the extent that any such prohibition,limitation, breach, default or conflict would not reasonably be expected to havea material adverse effect on the Purchased Assets. This Agreement has been, andon the Closing Date the Other Agreements will have been, duly executed anddelivered by Seller and constitutes, or, in the case of the Other Agreements,will constitute, the legal, valid and binding obligation of Seller, enforceableagainst Seller in accordance with their respective terms, except asenforceability may be limited or affected by applicable bankruptcy, insolvency,moratorium, reorganization or other laws of general application relating to oraffecting creditors’ rights generally. 5.3 Inventory, Equipment and Raw Materials. The Raw Materials, referencesand standards, and Stock-in-Trade transferred pursuant to Section 2.1 are ingood condition, except as would not reasonably be expected to have a materialadverse effect on such Raw Materials, references and standards orStock-in-Trade, respectively. The Inventory is, in all material respects, ingood and merchantable condition (it being understood that for purposes of theforegoing representation, any Loss shall be deemed immaterial, unless theaggregate amount arising out of such Loss is greater than $50,000), has beenmanufactured and stored in compliance with all applicable laws and regulations,and conforms to all material Governmental Authorizations; provided, however,that the foregoing representation shall be subject to the Buyer’s compliancewith any and all applicable laws and regulations relating to labeling andpackaging of the Inventory. 5.4 Title. The Purchased Assets are owned beneficially by Seller with goodand marketable title thereto, free and clear of all Encumbrances. At theClosing, Buyer will receive legal and beneficial title to all of the PurchasedAssets (except for (i) Contracts or any other property or rights included in thePurchased Assets for which a necessary consent has not been obtained and (ii)the Transferred Intellectual Property, the title of which is addressedexclusively in Section 5.5 hereof), free and clear of all Encumbrances (exceptfor liens for Taxes not yet due and payable or liens contemplated by theSecurity Agreement), except the Assumed Liabilities and except as set forth onSchedule 5.4 and subject to obtaining any consents of Persons listed on Schedule5.7. 5.5 Intellectual Property. Except as set forth on Schedule 5.5, theTransferred Intellectual Property is owned free and clear of all Encumbrances orhas been duly licensed for use by Seller. Except as set forth on Schedule 5.5,to Seller’s Knowledge, the Transferred Intellectual Property has not been and isnot the subject of any pending adverse claim or any threatened litigation orclaim of infringement. To Seller’s Knowledge, except as set forth on Schedule5.5, the Transferred Intellectual Property does not materially infringe on anyIntellectual Property Rights of any third party. 5.6 Litigation. Except as set forth on Schedule 5.6, there is nolitigation, proceeding, claim or governmental investigation pending or, toSeller’s Knowledge, threatened solely or primarily with respect to theProducts. 11 5.7 Consents. No notice to, filing with, authorization of, exemption by,or consent of any Person is required for Seller to consummate the transactionscontemplated hereby. 5.8 Brokers, Etc. No broker or investment banker acting on behalf ofSeller or under the authority of Seller is or will be entitled to any broker’sor finder’s fee or any other commission or similar fee directly or indirectlyfrom Seller or Buyer in connection with any of the transactions contemplatedherein, other than any fee that is the sole responsibility of Seller. 5.9 Financial Information. The unaudited statements of net revenue for thePurchased Assets for the years ended December 31, 2003 and December 31, 2004 (i)were prepared in accordance with GAAP as applied to the Seller’s consolidatedfinancial statements and (ii) present fairly in all material respects the netrevenues for the Products. The costed bill of materials for the Products for2004 (i) was prepared in a manner consistent with Seller’s financial policiesand (ii) fairly reflects the cost to manufacture the Products in Seller’sfacilities according to the volume and budget in place at the time the costswere established. The data on Schedule 5.9 with respect to the sales of Productsis complete and accurate in all material respects. 5.10 Absence of Undisclosed Liabilities. To Seller’s Knowledge, Seller hasnot incurred any material liabilities or obligations with respect to thePurchased Assets (whether accrued, absolute, contingent or otherwise), whichcontinue to be outstanding, except as incurred in the ordinary course ofbusiness. 5.11 Absence of Unusual Changes and Unusual Transactions. Since January31, 2006, except as would not reasonably be expected to have a material adverseeffect on the Purchased Assets, there has not been any material change in thefinancial conditions, methods of operation, working capital, assets, employmentpolicies or practices or prospects of the Purchased Assets other than changes inthe ordinary course of business. 5.12 Governmental Authorizations. Schedule 5.12 sets forth a complete listof the material Governmental Authorizations. The Governmental Authorizationslisted in Schedule 5.12 are all the authorizations required to be in materialcompliance with all laws applicable to the Purchased Assets. The GovernmentalAuthorizations are in full force and effect in accordance with their terms, andthere have been no material violations of such Governmental Authorizations, noproceedings are pending or, to the Knowledge of the Seller, threatened, whichcould result in their revocation or limitation and all steps have been taken andfilings made on a timely basis with respect to each Governmental Authorizationand its renewal; in each case, except as would not reasonably be expected tohave a material adverse effect on the Purchased Assets. 5.13 Contracts. All current and complete copies of all Contracts have beendelivered to or made available to the Buyer. The Contracts are all in full forceand effect and, to Seller’s Knowledge, there are no outstanding defaults orviolations under such Contracts on the part of the Seller or, to the Knowledgeof the Seller, on the part of any other party to such Contracts and there are nocurrent or pending negotiations with respect to the renewal, repudiation oramendment of any Contract. 12 5.14 Tax Matters. In each case except as would not reasonably be expectedto have a material adverse effect on the Purchased Assets: (a) To Seller’s Knowledge, no failure, if any, of the Seller to duly and timely pay all Taxes, including all installments on account of Taxes for the current year, that are due and payable by it will result in an Encumbrance on the Purchased Assets; (b) To Seller’s Knowledge, there are no proceedings, investigations, audits or claims now pending or threatened against the Seller in respect of any Taxes, and there are no matters under discussion, audit or appeal with any governmental authority relating to Taxes, which will result in an Encumbrance on the Purchased Assets; (c) To Seller’s Knowledge, the Seller has duly and timely withheldall Taxes and other amounts required by law to be withheld by it relating to thePurchased Assets (including Taxes and other amounts relating to the PurchasedAssets required to be withheld by it in respect of any amount paid or creditedor deemed to be paid or credited by it to or for the account or benefit of anyPerson, including any employees, officers or directors and any non-residentPerson), and has duly and timely remitted to the appropriate GovernmentalAuthority such Taxes and other amounts required by law to be remitted by it; and (d) To Seller’s Knowledge, the Seller or Seller’s Affiliates hasduly and timely collected all amounts on account of any sales or transfer taxes,including goods and services, harmonized sales and provincial or territorialsales taxes with respect to the Purchased Assets, required by law to becollected by it and has duly and timely remitted to the appropriate GovernmentalAuthority any such amounts required by law to be remitted by it. 5.15 Cell Banks. The Working Cell Banks are in viable condition as of the Closing. TheMaster Cell Banks have been stored following quality procedures in accordancewith current good manufacturing practice (cGMP). 5.16 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS ARTICLE 5,SELLER IS MAKING NO REPRESENTATION OR WARRANTY AS TO THE PURCHASED ASSETS ANDBUYER ACKNOWLEDGES AND AGREES THAT, EXCEPT AS OTHERWISE PROVIDED HEREIN, SELLERIS SELLING AND CONVEYING THE PURCHASED ASSETS ON AN “AS IS, WHERE IS” BASIS.EXCEPT TO THE EXTENT OF THE EXPRESS REPRESENTATIONS, WARRANTIES, AGREEMENTS ANDCOVENANTS CONTAINED IN THIS AGREEMENT, BUYER IS ACQUIRING THE PURCHASED ASSETSIN RELIANCE ON ITS OWN INVESTIGATION AND ON AN “AS IS, WHERE IS” BASIS ANDWITHOUT RECOURSE AND WITHOUT ANY REPRESENTATION OR WARRANTY OF MERCHANTABILITY,FITNESS FOR ANY PARTICULAR PURPOSE, NON INFRINGEMENT OR ANY OTHER IMPLIED OREXPRESS WARRANTIES WHATSOEVER. For greater certainty, nothing in this Section5.16 shall in any way limit Seller’s indemnification obligations as set forth inArticle 10. 13 ARTICLE 6 Representations and Warranties of Buyer Buyer represents and warrants to Seller as follows: 6.1 Organization. Buyer is a corporation duly incorporated and validlyexisting in good standing under the laws of the State of Delaware, dulyqualified to transact business as a foreign corporation in all jurisdictionsexcept where the failure to be so qualified would not reasonably be expected tohave a material adverse effect on Buyer, and with all requisite corporate powerand authority to own, lease and operate its properties and to carry on itsbusiness as now being conducted. 6.2 Due Authorization. Buyer has full corporate power and authority toexecute, deliver and perform its obligations under this Agreement and the OtherAgreements and the execution and delivery of this Agreement and the OtherAgreements and the performance of all of its obligations hereunder andthereunder has been duly authorized by Buyer. The signing, delivery andperformance of this Agreement and the Other Agreements by Buyer is notprohibited or limited by, and will not result in the breach of or a defaultunder, any provision of the Articles of Incorporation or By-Laws of Buyer or ofany order, writ, injunction or decree of any court or governmentalinstrumentality. This Agreement has been, and on the Closing Date the OtherAgreements will have been, duly executed and delivered by Buyer and constitutes,or, in the case of the Other Agreements will constitute, the legal, valid andbinding obligations of Buyer, enforceable against Buyer in accordance with theirrespective terms, except as enforceability may be limited or affected byapplicable bankruptcy, insolvency, moratorium, reorganization or other laws ofgeneral application relating to or affecting creditors’ rights generally. 6.3 Consents. Except as set forth on Schedule 6.3, no notice to, filingwith, authorization of, exemption by, or consent of, any Person is required forBuyer to consummate the transactions contemplated hereby. 6.4 Litigation. There is no litigation, proceeding, claim or governmentalinvestigation pending or, to Buyer’s knowledge, threatened relating to oraffecting Buyer’s ability to purchase the Purchased Assets or assume the AssumedLiabilities relating thereto. 6.5 Breach of Representations and Warranties. Buyer has no knowledge ofany breach, or the inaccuracy, of any of the representations or warranties ofSeller set forth in this Agreement. 6.6 Brokers, Etc. Except for fees and expenses which shall be the soleresponsibility of Buyer, no broker or investment banker acting on behalf ofBuyer or Buyer’s Affiliates is or will be entitled to any broker’s or finder’sfee or any other commission or similar fee directly or indirectly in connectionwith any of the transactions contemplated hereby. 14 6.7 Independent Investigation. In making the decision to enter into thisAgreement and the Other Agreements and to consummate the transactionscontemplated hereby and thereby, other than reliance on the representations,warranties, covenants and obligations of Seller set forth in this Agreement andin the Other Agreements, Buyer has relied solely on its own independentinvestigation, analysis and evaluation of the Purchased Assets and AssumedLiabilities (including Buyer’s own estimate and appraisal of the value of thefinancial condition, assets, operations and prospects thereof). Buyer confirmsto Seller that Buyer is sophisticated and knowledgeable in the business in whichBuyer intends to use the Purchased Assets and is capable of evaluating thematters set forth above. Nothing in this Section 6.7, shall limit in any way theability of Buyer to rely upon the express representations and warranties ofSeller set forth in this Agreement. 6.8 Indebtedness. Other than as set forth in Schedule 6.8, neither Buyernor its Affiliates have any Indebtedness. For purposes of this section,”Indebtedness” shall mean (a) all indebtedness of the Buyer or its Affiliates,whether owed to a bank or any other Person, including, without limitation,indebtedness for borrowed money and capitalized equipment leases and (b) anyinterest on any indebtedness referred to in clause (a) that has accrued andremains unpaid beyond the due date therefor. ARTICLE 7 Pre-Closing Covenants of Seller and Buyer 7.1 Corporate and Other Actions. Each of Seller and Buyer shall take, orshall cause its respective Affiliates to take, all necessary corporate actionrequired to fulfill its obligations under this Agreement and the OtherAgreements and the transactions contemplated hereby and thereby. 7.2 Consents and Approvals. Each of Seller and Buyer shall use itsreasonable best efforts to obtain all necessary consents and approvals to theperformance of its obligations under this Agreement and the Other Agreements andthe transactions contemplated hereby and thereby. Each of Seller and Buyer shallmake all filings, applications, statements, notices and reports to all federal,state, local or foreign government agencies or entities which are required to bemade or given prior to the Closing Date by or on behalf of Seller or Buyerpursuant to any applicable law, statute, ordinance, regulation or rule inconnection with this Agreement and the Other Agreements and the transactionscontemplated hereby and thereby. 7.3 Competition Law Filings. Each of Buyer and Seller shall promptlyprepare and file any notification and report form required under the HSR Act andany notification or other form required to be filed under any law or regulationof any foreign national or supra-national competition authority, and regulationspromulgated thereunder, if applicable, and any further filing pursuant theretoas may be necessary. 15 7.4 Access to Information. Seller will permit representatives of Buyerfrom and after the date hereof up to the Closing Date to have access at allreasonable times to the books, accounts, records, properties, operations,inventories and facilities of every kind to the extent pertaining to thePurchased Assets, and will furnish Buyer with such financial and operating dataconcerning the Purchased Assets as Buyer shall from time to time reasonablyrequest, subject to any confidentiality agreements entered into by Seller;provided that under no circumstances will Seller permit Buyer to have access toTax returns, including related work papers, filed by Seller or its Affiliates. 7.5 Ordinary Course of Business. Subsequent to the date hereof and priorto the Closing Date, Seller will use reasonable efforts to continue to operateand/or use the Purchased Assets in the usual and normal course consistent withpast practice and to maintain the Purchased Assets in substantially the samemanner as heretofore maintained. ARTICLE 8 Conditions 8.1 Conditions to Obligations of Seller. The obligations of Seller toconsummate the transactions contemplated by this Agreement shall be subject tofulfillment at or prior to the Closing of the following conditions (any one ormore of which may be waived in whole or in part by Seller): (a) Performance of Agreements and Conditions. All agreements and covenants to be performed and satisfied by Buyer hereunder on or prior to the Closing Date shall have been duly performed and satisfied by Buyer in all material respects. (b) Representations and Warranties True. The representations and warranties of Buyer contained in this Agreement that are qualified as to materiality shall be true and correct, and all other representations and warranties of Buyer contained in this Agreement shall be true and correct except for breaches of, or inaccuracies in, such representations and warranties that, in the aggregate, would not have a material adverse effect on the expected benefits to Seller of the transactions contemplated by this Agreement taken as a whole, in each such case on and as of the Closing Date, with the same effect as though made on and as of the Closing Date, and there shall be delivered to Seller on the Closing Date a certificate, in form and substance reasonably satisfactory to Seller and its counsel duly signed by the President or Vice President of Buyer, to that effect. (c) Payment of Purchase Price. Buyer shall have paid the Purchase Price and assumed the Assumed Liabilities as provided in Section 4.2(b). (d) HSR Waiting Period. Any applicable waiting period under the HSR Act shall have expired without action by the Justice Department or the Federal Trade Commission to prevent consummation of this Agreement or shall have been terminated earlier. (e) Foreign Competition Laws. Any necessary approvals shall have been received or any applicable period for action shall have expired under the applicable laws 16 or regulations of foreign national or supra-national competition authorities set forth on Schedule 6.7. (f) No Action or Proceeding. No legal or regulatory action or proceeding shall be pending or threatened by any Person to enjoin, restrict or prohibit the purchase and sale of the Purchased Assets contemplated hereby. No order, judgment or decree by any court or regulatory body shall have been entered in any action or proceeding instituted by any party that enjoins, restricts, or prohibits this Agreement or the complete consummation of the transactions as contemplated by this Agreement. (g) Other Agreements. Buyer shall have delivered to Seller a duly executed copy of each of the Other Agreements. (h) No Material Adverse Change. There shall not have been any material adverse change in Seller’s business, financial condition, prospects, assets or operations relating to the Purchased Assets. (i) Management Approval. Seller shall have obtained the necessary approval to consummate the transactions contemplated hereby from its management. 8.2 Conditions to Obligations of Buyer. The obligations of Buyer toconsummate the transactions contemplated by this Agreement shall be subject tofulfillment at or prior to the Closing of the following conditions (any one ormore of which may be waived in whole or in part by Buyer): (a) Performance of Agreements and Covenants. All agreements and covenants to be performed and satisfied by Seller hereunder on or prior to the Closing Date shall have been duly performed and satisfied by Seller in all material respects. (b) Representations and Warranties True. The representations and warranties of Seller contained in this Agreement that are qualified as to materiality shall be true and correct, and all other representations and warranties of Seller contained in this Agreement shall be true and correct except for breaches of, or inaccuracies in, such representations and warranties that, in the aggregate, would not have a material adverse effect on the Purchased Assets taken as a whole, in each such case on and as of the Closing Date with the same effect as though made on and as of the Closing Date, and there shall be delivered by Seller on the Closing Date a certificate, in form and substance reasonably satisfactory to Buyer and its counsel, duly signed by an officer of Seller, to that effect. (c) Cell Bank Viability. The Working Cell Banks shall have been certified as being in viable condition in accordance with the procedures set forth in the Testing Procedures. (d) HSR Waiting Period. Any applicable waiting period under the HSR Act shall have expired without action by the Justice Department or the Federal Trade Commission to prevent consummation of this Agreement or shall have been terminated earlier. 17 (e) Foreign Competition Laws. Any necessary approvals shall have been received or any applicable period for action shall have expired under the applicable laws or regulations of foreign national or supra-national competition authorities set forth on Schedule 6.7. (f) No Action or Proceeding. No legal or regulatory action or proceeding shall be pending or threatened by any Person to enjoin, restrict or prohibit the purchase and sale of the Purchased Assets contemplated hereby. No order, judgment or decree by any court or regulatory body shall have been entered in any action or proceeding instituted by any party that enjoins, restricts, or prohibits this Agreement or the complete consummation of the transactions as contemplated by this Agreement. (g) Other Agreements. Seller shall have delivered to Buyer a duly executed copy of each of the Other Agreements. (h) Board Approval. Buyer shall have obtained the necessary approval to consummate the transactions contemplated hereby from its board of directors. (i) Material Adverse Change. There shall not have been a material adverse change in the Seller’s business, financial condition, prospects, assets or operations relating to the Purchased Assets. ARTICLE 9 Post-Closing Covenants, Other Agreements 9.1 Assumed Liabilities. Buyer agrees to keep a list describing in detailthe Assumed Liabilities paid by Buyer or Buyer’s Affiliates and to retain alldocumentation supporting actual payment of each Assumed Liability. Buyer willsubmit such list and such documentation to Seller within thirty (30) days afterthe end of each calendar quarter until the Promissory Note has been paid,satisfied or discharged by Buyer or Buyer’s Affiliates. 9.2 Availability of Records. After the Closing, Buyer, shall makeavailable to Seller as reasonably requested by Seller, its agents andrepresentatives, or as requested by any taxing authority or any governmentalauthority, all information, records and documents relating to the PurchasedAssets for all periods prior to Closing and shall preserve all such information,records and documents until the later of: (a) six (6) years after the Closing;(b) the expiration of all statutes of limitations for Taxes for periods prior tothe Closing, or extensions thereof applicable to Seller for Tax information,records or documents; or (c) the required retention period for all governmentcontract information, records or documents. Buyer shall also make available toSeller, as reasonably requested by Seller at Seller’s cost, personnelresponsible for preparing or maintaining information, records and documents, inconnection with Tax matters, governmental contracts, litigation or potentiallitigation, including without limitation, product liability, general insuranceliability and automobile insurance liability. Prior to destroying any recordsrelated to Seller for the period prior to the Closing, Buyer shall notify Sellerninety (90) days in advance of any such proposed destruction of its intent todestroy such records, and Buyer will permit Seller to retain any such records.With respect to any litigation and claims that are Excluded 18Liabilities, Buyer shall render at Seller’s cost all reasonable assistance thatSeller may request in defending such litigation or claim and shall makeavailable to Seller personnel who most knowledgeable about the matter inquestion. 9.3 Use of Trade or Service Marks. Other than pursuant to the InventoryTrademark License Agreement, neither Buyer nor any of Buyer’s Affiliates shalluse or permit its distributors to use the name “Abbott Laboratories” or anyother corporate, trade or service marks or names owned or used by Seller orSeller’s Affiliates, or the ABBOKINASE(R) trademark, unless such marks or namesare specifically included in the Purchased Assets. Except to the extentindicated on Schedule 2.1(f), all Product packaging of the Purchased Assets asof the Closing used to package Products manufactured by Buyer or any Affiliateof Buyer after the Closing shall bear a new code identification that indicatesthe Products were manufactured by Buyer. 9.4 Tax Matters (a) Bifurcation of Taxes. Subject to Section 3.4, Seller and its Affiliates shall be solely liable for all Taxes imposed upon Seller attributable to the Purchased Assets for all taxable periods ending on or before the Closing Date. Buyer and its Affiliates shall be solely liable for any Taxes imposed upon Buyer attributable to the Purchased Assets for any taxable year or taxable period commencing after the Closing Date. (b) Transfer Taxes. Buyer shall be liable for all sales, use, transfer and documentary taxes and recording and filing fees applicable to the transfer of the Purchased Assets. If (i) Buyer, in accordance with the Tax laws of the applicable states of the United States, timely furnishes to Seller a resale certificate evidencing its purchase of the Inventory pursuant to this Agreement for the purpose of resale in the ordinary course of Buyer’s business, and (ii) the other Purchased Assets are exempt from sales, use or similar Taxes, Seller agrees not to collect sales Tax with respect to such Purchased Assets. (c) Cooperation and Records. After the Closing Date, Buyer and Seller shall cooperate in the filing of any Tax returns or other Tax-related forms or reports, to the extent any such filing requires providing each other with necessary relevant records and documents relating to the Purchased Assets. Seller and Buyer shall cooperate in the same manner in defending or resolving any Tax audit, examination or Tax-related litigation. Buyer and Seller shall cooperate in the same manner to minimize any transfer, sales and use Taxes. Nothing in this Section shall give Buyer or Seller any right to review the other’s Tax returns or Tax related forms or reports. (d) Inventory Resale Certificates. At the Closing, Buyer shall execute and deliver to Seller resale certificates for all inventory items transferred to Buyer. (e) Bulk Sales Laws. Seller and Buyer waive compliance with bulk sales laws for tax purposes. 19 9.5 Chargebacks. Seller shall be responsible for all Seller Chargebacks,and Buyer shall be responsible for all Buyer Chargebacks. In the event a SellerChargeback is charged to Buyer, Buyer shall honor such Seller Chargeback, Buyershall invoice Seller for such Buyer-honored Seller Chargebacks on a monthlybasis, and Seller shall pay such invoiced amounts to Buyer within thirty (30)days of the date of any invoice. In the event a Buyer Chargeback is charged toSeller, Seller shall honor such Buyer Chargeback, Seller shall invoice Buyer forsuch Seller-honored Buyer Chargebacks on a monthly basis, and Buyer shall paysuch invoiced amounts to Seller within thirty (30) days of the date of anyinvoice provided that such invoice includes a lot number for each Product forwhich a Chargeback was paid. In the event that both Buyer and Seller pay aChargeback to a customer, then as between Buyer and Seller, the party that soldthe lot to such customer shall be responsible for reconciling any such doublepayment. 9.6 Non-competition by Seller. Seller covenants and agrees that neither itnor any of its Affiliates or related parties will, directly or indirectly, onbehalf of itself or any other party, sell, market, promote, distribute, license,research or develop in the United States any Thrombolytic Therapy Product for aperiod of three (3) years commencing on the Closing Date, or invest in (otherthan Buyer), participate in or assist any other entity with respect to any ofthe foregoing. Notwithstanding the foregoing, nothing in this Section 9.6 shallprevent Seller from (i) acquiring a third party that derives 10% or less of itsannual net sales from the development, sale, marketing, promotion ordistribution of any Thrombolytic Therapy Product; or (ii) engaging in research,developing, selling, marketing, promoting and/or distributing any product thatmay be used on an off-label basis as a Thrombolytic Therapy Product, providedthat any such research, development, promoting and marketing is not intended foruse of the product as a Thrombolytic Therapy Product. 9.7 Regulatory Transfer. Seller agrees to make available to Buyer atSeller’s offices all portions of the NDA 76-1021 file that Seller has notpreviously delivered to Buyer pursuant to Section 4.2(c) as soon as practicablebut in no event later than 180 days after the Closing Date. 9.8 Post-Closing Delivery. Seller agrees to store the tangible PurchasedAssets in its facilities for the benefit of Buyer for 90 days after Closing atno cost to the Buyer; thereafter Buyer shall pay Seller an amount equal to$1,000 per day for such storage. Buyer agrees to arrange for physical deliveryto Buyer of the tangible Purchased Assets in Seller’s possession within such 90day period. Buyer and Seller acknowledge that title and risk of loss withrespect to all Purchased Assets shall pass to Buyer at Closing. Seller agrees touse commercially reasonable efforts to preserve and maintain the tangiblePurchased Assets in good working condition and to protect such Purchased Assetsagainst spoilage, deterioration and other wasting. 9.9 Transition Services. Seller agrees to make available to Buyer, at nocost to Buyer, personnel who are familiar with the regulatory compliance,quality assurance, medical reporting and commercialization relating to theProduct for up to a maximum of 300 manhours for a period of time beginning 5days after the Closing and ending on the date that is six (6) months followingthe Closing Date, pursuant to which Seller personnel will provide explanationsand answer questions that are reasonably necessary to allow Buyer to effectivelyidentify, organize and utilize the Purchased Assets that Buyer has acquired fromSeller. In the event that Buyer desires in excess of 300 manhours for suchassistance, and Seller agrees to provide such additional assistance, Buyer shallpay to Seller $250 per additional manhour for up to a maximum of 200 20additional manhours. Buyer will reimburse Seller for all reasonable costs andexpenses relating to the travel and lodging incurred by such personnel (whichshall not be included in the fee described above). Seller will use commerciallyreasonable efforts to provide these services to Buyer in a manner substantiallysimilar to industry standards, except to the extent the parties may otherwiseagree. The obligations of Seller under Section 2.5 shall be provided withoutcost to Buyer and are in addition to the services to be provided pursuant tothis Section 9.9. 9.10 No Other Compensation. Buyer hereby agrees that the terms of this Agreement and the OtherAgreements fully define all consideration, compensation and benefits, monetaryor otherwise, to be paid, granted or delivered by Buyer to Seller in connectionwith the transactions contemplated herein and therein. Buyer has not previouslypaid nor entered into any other commitment to pay, whether orally or in writing,any Seller employee, directly or indirectly, any consideration, compensation orbenefits, monetary or otherwise, in connection with the transaction contemplatedherein. ARTICLE 10 Indemnification and Survival 10.1 Indemnification by Seller. (a) Seller’s Indemnity. To the extent set forth in this Section 10.1, Seller agrees to indemnify and hold harmless Buyer and its Affiliates at all times against and in respect of all losses, liabilities, costs and expenses (including, without limitation, reasonable attorneys’ fees) (collectively, “Losses”) which Buyer or its Affiliates may suffer or incur to the extent arising out of or based upon (i) any breach of any of the representations and warranties of Seller set forth in this Agreement, (ii) any breach of any of the covenants and agreements of Seller set forth in this Agreement, (iii) any Excluded Liability, or (iv) the production, development, trial, research, marketing use, or distribution of the Products prior to the Closing Date. (b) Limitations on Seller’s Indemnity. (i) Seller shall not be liable for any Loss described in Section 10.1(a)(i) until the aggregate of all such Losses for which the Seller is liable are in excess of $250,000. Notwithstanding the foregoing, Seller shall not indemnify or hold harmless the Buyer or its Affiliates against any such individual Loss unless such Loss exceeds Fifty Thousand U.S. dollars ($50,000) and no such individual Loss of less than Fifty Thousand Dollars ($50,000) (exclusive of attorneys’ fees) shall be considered in determining whether the aggregate Losses exceed the deductible set forth in the preceding sentence. (ii) Seller’s aggregate liability for all Losses described in Section 10.1(a)(i) shall not exceed Five Million U.S. dollars ($5.0 million); provided, however, that upon Buyer’s satisfaction of all of its Obligations (as defined in the Promissory Note), Seller’s liability for such Losses shall not exceed Twenty Million U.S. dollars ($20.0 million). 21 (iii) Neither Seller nor Seller’s Affiliates shall have liability to Buyer or Buyer’s Affiliates for any consequential, incidental or punitive damages, and Losses indemnifiable hereunder shall not include such damages. (c) Notice of Claims. Buyer shall promptly notify Seller in writing of all matters which may give rise to the right to indemnification hereunder upon becoming aware of any such matters, it being understood that if Seller does not receive notice of any matter known to Buyer and as to which Buyer or its Affiliates are entitled to indemnification hereunder in time to contest the determination of any such liability which is susceptible to being successfully contested, Seller shall be relieved of its responsibilities hereunder to the extent such failure to deliver notice shall have harmed Seller. Buyer shall not admit any liability with respect to, or settle, compromise or discharge, any such matter covered by this Section 10.1 without Seller’s prior written consent (which shall not be unreasonably withheld or delayed). Seller shall have the right, with the consent of Buyer (which shall not be unreasonably withheld or delayed), to settle all indemnifiable matters related to claims by third parties which are susceptible to being settled, and to defend (without the consent of Buyer) through counsel of its own choosing, at its own expense, any action which may be brought by a third party in connection therewith; provided, however, that Buyer shall have the right to have its counsel participate fully in such defense at its own expense. Buyer and Seller shall keep each other informed of all settlement negotiations with third parties regarding the provisions hereof and of the progress of any litigation with third parties regarding the provisions hereof. Buyer and Seller shall permit each other reasonable access to books and records and otherwise cooperate with all reasonable requests of each other in connection with any indemnifiable matter resulting from a claim by a third party. 10.2 Indemnification by Buyer. (a) Buyer’s Indemnity. Buyer agrees to indemnify and hold harmless Seller and its Affiliates at all times against and in respect of Losses which Seller and its Affiliates may suffer or incur to the extent arising out of or based upon: (i) any breach of any of the representations, warranties, covenants and agreements of Buyer set forth in this Agreement or the Other Agreements; (ii) any Assumed Liability; or (iii) the ownership of the Purchased Assets after the Closing Date (except Losses covered by Section 10.1(a)(iv)). 22 (b) Limitations on Buyer’s Indemnity. (i) Buyer shall not be liable for any Loss described in Section 10.2(a)(i) until the aggregate of all such Losses for which the Buyer is liable are in excess of $250,000. Notwithstanding the foregoing, Buyer shall not indemnify or hold harmless the Seller or its Affiliates against any such individual Loss unless such Loss exceeds Fifty Thousand U.S. dollars ($50,000) and no such individual Loss of less than Fifty Thousand Dollars ($50,000) (exclusive of attorneys’ fees) shall be considered in determining whether the aggregate Losses exceed the deductible set forth in the preceding sentence. (ii) Buyer’s aggregate liability for all Losses described in Section 10.2(a)(i) shall not exceed Five Million U.S. dollars ($5.0 million); provided, however, that upon Buyer’s satisfaction of all its Obligations (as defined in the Promissory Note), Buyer’s liability for such Losses shall not exceed Twenty Million U.S. dollars ($20.0 million). (iii) Neither Buyer nor Buyer’s Affiliates shall have liability to Seller or Seller’s Affiliates for any consequential, incidental or punitive damages, and Losses indemnifiable hereunder shall not include such damages. (c) Notice of Claims. Seller shall promptly notify Buyer in writing of all matters which may give rise to the right to indemnification hereunder upon becoming aware of any such matters, it being understood that if Buyer does not receive notice of any matter known to Seller and as to which Seller and its Affiliates is entitled to indemnification hereunder in time to contest the determination of any such liability which is susceptible to being successfully contested, Buyer shall be relieved of its responsibilities hereunder to the extent such failure to deliver notice shall have harmed Buyer . Seller shall not admit any liability with respect to, or settle, compromise or discharge any such matter covered by this Section 10.2 without Buyer’s prior written consent (which shall not be unreasonably withheld or delayed). Buyer shall have the right, with the consent of Seller (which shall not be unreasonably withheld or delayed), to settle all indemnifiable matters related to claims by third parties which are susceptible to being settled, and to defend (without the consent of Seller) through counsel of its own choosing, at its own expense, any action which may be brought by a third party in connection therewith; provided, however, that Seller shall have the right to have its counsel participate fully in such defense at its own expense. Buyer and Seller shall keep each other informed of all settlement negotiations with third parties regarding the provisions hereof and of the progress of any litigation with third parties regarding the provisions hereof. Buyer and Seller shall permit each other reasonable access to books and records and otherwise cooperate with all reasonable requests of each other in connection with any indemnifiable matter resulting from a claim by a third party. 10.3 Survival. The representations and warranties of the parties containedherein shall survive the Closing for a period of eighteen (18) months at whichtime they shall expire; provided, however, that claims previously made inwriting with respect to breaches of such representations and warranties shall beindemnifiable in accordance with this Article 10. No 23claim may be made based upon an alleged breach of any of such representations orwarranties whether for indemnification in respect thereof or otherwise, unlesswritten notice of such claim, in reasonable detail, is given to Buyer or toSeller, as the case may be, within said eighteen (18) months period followingthe Closing. The indemnification obligations of Seller for Excluded Liabilitiesshall survive the Closing indefinitely. 10.4 Exclusive Remedy. From and after the Closing, the rights and remediesset forth in this Article 10 shall constitute the sole and exclusive rights andremedies of Buyer and Seller with respect to this Agreement, the events givingrise to this Agreement and the transactions contemplated hereby, except asprovided in Section 2.5. 10.5 Net Losses and Subrogation. (a) Notwithstanding anything contained herein to the contrary, the amount of any Losses incurred or suffered by a Person entitled to indemnification hereunder (an “Indemnified Person”) shall be calculated after giving effect to: (i) any insurance proceeds received by the Indemnified Person (or any of its Affiliates) with respect to such Losses; (ii) any Tax benefit actually realized by the Indemnified Person (or any of its Affiliates) arising from the facts or circumstances giving rise to such Losses; and (iii) any recoveries obtained by the Indemnified Person (or any of its Affiliates) from any other third party. Each Indemnified Person shall exercise its commercially reasonable efforts to obtain such proceeds, benefits and recoveries. If any such proceeds, benefits or recoveries are received by an Indemnified Person (or any of its Affiliates) with respect to any Losses after the Indemnified Person (or any Affiliate) has received the benefit of any indemnification hereunder with respect thereto, the Indemnified Person (or such Affiliate) shall pay to the Person providing the indemnification (the “Indemnifying Person”) the amount of such proceeds, benefits or recoveries (up to the amount of the Indemnifying Person’s payment). (b) Upon making any payment to an Indemnified Person in respect of any Losses, the Indemnifying Person will, to the extent of such payment, be subrogated to all rights of the Indemnified Person (and its Affiliates) against any third party in respect of the Losses to which such payment relates. Such Indemnified Person (and its Affiliates) and Indemnifying Person will execute upon request all instruments reasonably necessary to evidence or further perfect such subrogation rights. 10.6 Insurance. As of the date hereof, Buyer is the named insured underinsurance policies that are in full force and effect from an insurance companywith an A.M. Best rating of A++ or A+ (superior) providing the following minimumlevels of coverage: general comprehensive liability, including productliability, insurance covering each occurrence of bodily injury and propertydamage in an amount of not less than Five Million Dollars ($5,000,000) peroccurrence and not less than Five Million Dollars ($5,000,000) in the aggregate.Buyer shall keep such insurance policies in force during the term of itsindemnity obligations to the Seller under this Agreement and, within sixty (60)days of the Closing Date, shall obtain general comprehensive liability,including product liability, insurance covering each occurrence of bodily injuryand property damage in an amount of not less than Five Million Dollars($5,000,000) per occurrence and not less than Ten Million Dollars ($10,000,000)in the 24aggregate. Buyer shall (a) cause the insurer to endorse the insurance policy toprovide for written notification to the Seller by the insurer not less thanthirty (30) days prior to cancellation, expiration or modification and (b) namethe Seller as an additional insured on the insurance policy. Buyer shall furnishthe Seller with a certificate of insurance evidencing compliance with thisSection 10.6 and referencing this Agreement within sixty (60) days of theClosing Date or, in the event of insurance renewal, within ten (10) days of suchrenewal. ARTICLE 11 Termination 11.1 Termination of Agreement. This Agreement may be terminated at anytime prior to the Closing Date with the mutual consent of Buyer and Seller. 11.2 Automatic Termination. This Agreement shall terminate automaticallyif the Closing Date shall not have occurred on or before April 28, 2006, or suchlater date as shall have been agreed to by the parties hereto. 11.3 Continuing Effectiveness. If this Agreement shall be terminated asherein set forth, both parties agree that they will remain obligated under, andwill comply with, the provisions of Article 10 and Sections 12.2, 12.3, 12.4,12.7, 12.9, 12.13, and 12.15. ARTICLE 12 Miscellaneous 12.1 Assignment. This Agreement shall be binding upon and inure to thebenefit of the parties hereto and their respective successors and assigns;provided, however, that no assignment shall be made by either party without theprior express written consent of the other party. Notwithstanding the foregoing,either party may assign its rights and obligations under this Agreement withoutsuch consent to an Affiliate or in connection with a sale, merger or othertransaction involving a transfer of substantially all of its assets; providedthat, Buyer may not assign its rights and obligations under this Agreementwithout the prior written consent of Seller until such time as Buyer’sObligations (as defined in the Promissory Note) under the Promissory Note havebeen indefeasibly paid in full. 12.2 No Press Release Without Consent. No press release related to thisAgreement or the transactions contemplated herein, or other announcement toeither the customers or suppliers of Seller or investors or potential investorsin Buyer will be issued without the joint approval of Seller and Buyer, except:(a) any public disclosure which Seller or Buyer in its good faith judgmentbelieves is required by law, rule or regulation or by any stock exchange orinterdealer quotation system on which its securities are listed or quoted (inwhich case the party making the disclosure will use its reasonable best effortsto consult with the other party prior to making any such disclosure) and (b)that Seller may make an announcement related to this Agreement and thetransactions contemplated hereby to its employees. Buyer and Seller willcooperate to prepare a joint press release to be issued on the Closing Date or,upon the request of Seller, at the time of the signing of this Agreement. 25 12.3 Confidentiality. All information gained by either party concerningthe other as a result of the transactions contemplated hereby (“ConfidentialInformation”), including the execution and consummation of the transactionscontemplated hereby and the terms thereof, will be kept in strict confidence,subject to disclosures permitted pursuant to Section 12.2. All ConfidentialInformation will be used only for the purpose of consummating the transactionscontemplated hereby. Following the Closing, all Confidential Informationrelating to the Products disclosed by Seller to Buyer shall become theConfidential Information of Buyer, subject to the restrictions on use anddisclosure by Seller imposed under this Section 12.3. Neither Seller nor Buyershall, without having previously informed the other party about the form,content and timing of any such announcement, make any public disclosure withrespect to the Confidential Information or transactions contemplated hereby,except: (i) As may be required by (a) law, rule or regulation, (b) the Securities and Exchange Commission (the “SEC”), (c) the Securities Act or the Exchange Act, or (d) any listing agreement with the New York Stock Exchange, the National Association of Securities Dealers, Inc. or any national securities exchange to which Seller or Buyer as applicable, is subject; provided that, in any such event, the party required to make the disclosure will (I) provide the other party with prompt written notice of any such requirement so that such other party may seek a protective order or other appropriate remedy, (II) consult with and exercise in good faith all reasonable efforts to mutually agree with the other party regarding the nature, extent and form of such disclosure, (III) limit disclosure of Confidential Information to what is legally required to be disclosed, and (IV) exercise its best efforts to preserve the confidentiality of any such Confidential Information; or (ii) Upon prior written approval from Seller, Buyer may disclose the terms of this agreement and the transactions contemplated hereby to an actual or prospective lender, investor, partner or agent, subject to a non-disclosure agreement pursuant to which such lender, investor, partner or agent agrees to be bound by the terms of this Section 12.3. 12.4 Expenses. Subject to Section 9.4(b), each party shall bear its ownexpenses with respect to the transactions contemplated by this Agreement. 12.5 Severability. Each of the provisions contained in this Agreementshall be severable, and the unenforceability of one shall not affect theenforceability of any others or of the remainder of this Agreement. 12.6 Entire Agreement. This Agreement may not be amended, supplemented orotherwise modified except by an instrument in writing signed by all of theparties hereto. This Agreement, the Other Agreements and the ConfidentialityAgreement contain the entire agreement of the parties hereto with respect to thetransactions covered hereby, superseding all negotiations, prior discussions andpreliminary agreements made prior to the date hereof. 26 12.7 No Third Party Beneficiaries. This Agreement is for the sole benefitof the parties hereto and their permitted assigns and nothing herein, express orimplied (including Article 10), shall give or be construed to give to anyPerson, other than the parties hereto and such permitted assigns, any legal orequitable rights hereunder. 12.8 Waiver. The failure of any party to enforce any condition or part ofthis Agreement at any time shall not be construed as a waiver of that conditionor part, nor shall it forfeit any rights to future enforcement thereof. Anywaiver hereunder shall be effective only if delivered to the other party heretoin writing by the party making such waiver. 12.9 Governing Law. This Agreement shall be construed and enforced inaccordance with and governed by the laws of the State of Delaware without regardto the conflicts of laws provisions thereof. 12.10 Headings. The headings of the sections and subsections of thisAgreement are inserted for convenience only and shall not be deemed toconstitute a part hereof. 12.11 Counterparts. The parties may execute this Agreement in one or morecounterparts, and each fully executed counterpart shall be deemed an original. 12.12 Further Documents. Each of Buyer and Seller will, and will cause itsrespective Affiliates to, at the request of another party, execute and deliverto such other party all such further instruments, assignments, assurances andother documents as such other party may reasonably request in connection withthe carrying out of this Agreement and the transactions contemplated hereby. 12.13 Notices. All communications, notices and consents provided forherein shall be in writing and be given in person or by means of telex,facsimile or other means of wire transmission (with request for assurance ofreceipt in a manner typical with respect to communications of that type), byovernight courier or by mail, and shall become effective: (a) on delivery ifgiven in person; (b) on the date of transmission if sent by telex, facsimile orother means of wire transmission; (c) one (1) business day after delivery to theovernight service; or (d) four (4) business days after being mailed, with properpostage and documentation, for first-class registered or certified mail,prepaid. Notices shall be addressed as follows: If to Buyer, to: ImaRx Therapeutics, Inc. 1635 East 18th Street Tucson, Arizona 85719 Attn: Greg Cobb Facsimile Number: (520) 791-2437 27 with copies to: DLA Piper Rudnick Gray Cary LLP 701 Fifth Avenue, Ste 7000 Seattle, Washington 98104 Attn: Jeffrey E. Harmes Facsimile Number: (206) 839-4801 If to Seller, to: Abbott Laboratories 100 Abbott Park Road Building AP6D, Department 364 Abbott Park, Illinois 60064-6020 Attn: General Counsel Facsimile Number: (847) 938-6277 with copies to: Kirkland & Ellis LLP 200 East Randolph Drive Chicago, Illinois 60601 Attn: R. Scott Falk, P.C. Facsimile Number: (312) 861-2200provided, however, at the time of mailing or within three business daysthereafter there is or occurs a labor dispute or other event that mightreasonably be expected to disrupt the delivery of documents by mail, anycommunication, notice or consent provided for herein shall be given in person orby means of telex, facsimile or other means of wire transmission or by overnightcourier, and further provide that if any party shall have designated a differentaddress by notice to the others, then to the last address so designated. 12.14 Schedules. Buyer and Seller agree that any disclosure in anySchedule attached hereto shall (a) constitute a disclosure under each otherSchedule referred to herein for all purposes of this Agreement, whether or notsuch disclosure is specifically referenced within such other Schedule, if it isreasonably apparent on the face of the disclosure that it is applicable to anyparticular Schedule, and (b) not establish any threshold of materiality. Selleror Buyer may, from time to time prior to or at the Closing, by notice inaccordance with the terms of this Agreement, supplement or amend any Schedule,including one or more supplements or amendments to correct any matter whichwould constitute a breach of any representation, warranty, covenant orobligation contained herein. No such supplemental or amended Schedule shall bedeemed to cure any breach for purposes of Section 8.2(b). If, however, theClosing occurs, any such supplement and amendment will be effective to cure andcorrect for all other purposes any breach of any representation, warranty,covenant or obligation which would have existed if Seller or Buyer had not madesuch supplement or amendment, and all references to any Schedule hereto which issupplemented or amended as provided in this Section 12.14 shall for all purposesat and after the Closing be deemed to be a reference to such Schedule as sosupplemented or amended. 28 12.15 Construction. The language in all parts of this Agreement shall beconstrued, in all cases, according to its fair meaning. The parties acknowledgethat each party and its counsel have reviewed and revised this Agreement andthat any rule of construction to the effect that any ambiguities are to beresolved against the drafting party shall not be employed in the interpretationof this Agreement. Words in the singular shall be deemed to include the pluraland vice versa and words of one gender shall be deemed to include the othergender as the context requires. The terms “hereof,” “herein,” and “herewith” andwords of similar import shall, unless otherwise stated, be construed to refer tothis Agreement as a whole (including all of the Schedules and Exhibits hereto)and not to any particular provision of this Agreement. Article, Section, Exhibitand Schedule references are to the Articles, Sections, Exhibits, and Schedulesto this Agreement unless otherwise specified. Unless otherwise stated, allreferences to any agreement shall be deemed to include the exhibits, schedulesand annexes to such agreement. The word “including” and words of similar importwhen used in this Agreement shall mean “including, without limitation,” unlessthe context otherwise requires or unless otherwise specified. The word “or”shall not be exclusive. Unless otherwise specified in a particular case, theword “days” refers to calendar days. References herein to this Agreement or anyOther Agreement shall be deemed to refer to this Agreement or such OtherAgreement as of the date of such agreement and as it may be amended thereafter,unless otherwise specified. * * * * * * * * * * * 29 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to beexecuted by their respective duly authorized officers as of the date first abovewritten. IMARX THERAPEUTICS, INC. By:___________________________________________ Name: Evan C. Unger Title: President and Chief Executive Officer ABBOTT LABORATORIES By:___________________________________________ Name: Sean E. Murphy Title: Vice President, Global Licensing/ New Business Development SCHEDULE 1.1 – KNOWLEDGE PERSONSSELLER1. John Heden2. Mike Morrison3. Peter Bacher4. Patrick Podstawa5. Brian Braun6. Roberta Stockman7. Rolland Carlson SCHEDULE 2.1(b) – TRANSFERRED INTELLECTUAL PROPERTYPATENTS U.S. Patent No. 5,260,872 (the “Copeland Patent”) Wholly owned by Abbott Inventors: Copeland et al. Title: Automated Testing System Issue Date: November 9, 1993 Expiration Date: November 9, 2010 No foreign corresponding patent(s) have been filed.TRADEMARKSNone SCHEDULE 2.1(c) – CELL BANKS CELL LINE CD 7, CD 8 AND CD1 INVENTORIES 3/16/06 EXPLANTCELL LINE NO. OF CELLS x 10(6) APPROXIMATE NO. OF AMPULES- ——— ——————– ————————– CD 7 100 5 CD 8 274.6 14 SUBCULTURE 2CELL LINE NO. OF CELLS x 10(6) APPROXIMATE NO. OF AMPULES- ——— ——————– ————————– CD 7 21771 362 CD 8 4650 77 CD 1 41630 693 SCHEDULE 2.1(d)(i) – CONTRACTS1. Abbokinase Fill and Finish Agreement between Hospira, Inc. and Abbott Laboratories, dated April 16, 2004.2. Clinical Study Agreement by and among Southern Illinois University, Memorial Medical Center, St. John’s Hospital and Abbott Laboratories (Kim J. Hodgson, PI) dated November 25, 2003.3. Clinical Study Agreement between The University of Chicago and Abbott Laboratories (Tina Desai, PI) dated July 28, 2003. SCHEDULE 2.1(g) – SALES MATERIALS1. Seller’s Siebel CRM database of sales and other information relating to the Product in electronic format(1)2. Physician call records from the Product sales force3. Sales training materials relating to the Product4. Sales territory breakouts (i.e., number of reps/regions, assigned accounts) relating to sales of the Product5. Promotional literature relating to promotion of the Product6. Physician detail materials relating to the Product7. Launch meeting materials (i.e., slides, program, hand-outs, etc.) relating to the Product8. Product label and package inserts in electronic format- ———-(1) Seller’s transfer of the Siebel CRM database hereunder does not in anyway constitute a license or sublicense of any Siebel software product by Seller to Buyer or any of its Affiliates. SCHEDULE 2.1(h) – PRODUCT APPLICATIONS1. New Drug Application 76-1021.2. The following supplements to NDA 76-1021 have been approved or are pending approval by the Food and Drug Administration (the “FDA”).
Date Date Supplement Supplement Type of Supplement Number Submitted Supplement Supplement Description Approved- —————- ———– ————– ———————————————– ———-
S-076 12/31/01 PAS Provides for: (i) changes in the procurement 10/10/02 and processing of neonatal kidney cells; (ii) improvements in the manufacture and testing of the drug substance and drug product; (iii) revised release specifications for the drug substance and drug product; (iv) a revised lot release protocol; (v) withdrawal of the OPEN-CATH(R) dosage strengths; and (vi) revised labeling. Labeling revisions include updated information regarding product source and adverse reactions, as well as withdrawal of the coronary artery thrombosis and catheter clearance indications. S-083 05/02/03 CBE-30 Provides for the addition of a 0.45 (mu)m 09/25/03 pre-filter and a 0.22 (mu)m filtration step immediately prior to the ultrafiltration step in the urokinase isolation process. S-089 09/30/03 CBE-30 Provides for the storage of the CG-50 resin at 04/01/04 an alkaline pH as an alternative regeneration process to manage bioburden control. S-090 11/01/03 CBE-0 Provides for the replacement of the drug 05/03/04 substance relative amidolytic potency specification with an amidolytic potency specification; and to revise the drug product bacterial endotoxin test method.
S-092 1/6/04 CBE-0 Provides for the revision of the lot release 7/8/04 protocol to include changes to the drug substance specifications and drug product bacterial endotoxin test method. S-095 4/26/04 PAS Provides for the storage of drug substance at Pending SCHEDULE 2.1(j) – STOCK-IN-TRADEAbbokinase Lot# 15-342-S2 For Clinical Study M03-585180 vials in Abbott’s Clinical Warehouse120 vials with Clinical Study Cooperators SCHEDULE 2.1(k) – RAW MATERIALSAbbottCode Unit ofNumber Qty. Measure Code Description Retest- ——- ———— ——- ——————— ——72706 1.85 Ltr TRYPSIN 2 Year59384 12,582.00 Ltr Protein Hydrolysate 2 Year11379 100,000.00 gm Aminocaproic Acid NA19670 1,518,419.50 gm Dextrose 2 Year13156 52.99 lt Octyl Alcohol 2 Year13937 2,042.57 kg Ion Exchange Resin 2 Year16131 1,179,540.00 ml BEE 1 Year21442 1,139.00 lt Bovine Serum 1 Year22441 2,757,240.00 ug EGF, Growth Factor 3 Year23366 117,420.88 gm Dextran, Cross Linked 2 Year23373 95,128.60 gm Dextran, Cross Linked 2 Year24092 6,115.00 ml DMSO 2 Year33802 30,268.00 gm L-Glutamine 2 Year43740 327,231.00 gm Magnesium Sulfate 2 Year44488 3,565,915.00 gm MED-199 2 Year56664 5,944.20 gm Phenol Red 2 Year66340 1,570,960.00 gm Sodium Phosphate 2 Year72704 856.20 gm Trypsin Powder 2 Year74813 200,992.60 gm Vitamin BME 2 Year87324 13,575.00 lt Serum, Newborn Calf 1 Year SCHEDULE 2.5 – MIXED GPO CONTRACTS1. Agreement for Pharmaceutical Products by and between Abbott Laboratories Inc. and Broadlane, Inc., dated as of August 21, 2001. *2. Abbokinase(R) (urokinase) Contract between Good Samaritan Hospital and Abbott Laboratories Inc. dated as of June 25, 2003.3. Abbokinase(R) (urokinase) Contract between Kenosha Hospital and Medical Center and Abbott Laboratories Inc. dated as of Aug. 1, 2003.4. Abbokinase(R) (urokinase) Contract between Littleton Adventist Hospital and Abbott Laboratories Inc. dated as of Sept. 1, 2003.5. Abbokinase(R) (urokinase) Contract between Penrose St. Francis Health Center and Abbott Laboratories Inc. dated as of August 1, 2003.6. Abbokinase(R) (urokinase) Contract between Porter Adventist Hospital and Abbott Laboratories Inc. dated as of Sept. 1, 2003.7. Abbokinase(R) (urokinase) Contract between St. Anthony Central Hospital and Abbott Laboratories Inc. dated as of Oct. 1, 2003.8. Abbokinase(R) (urokinase) Contract between St. Catherine’s Hospital and Abbott Laboratories Inc. dated as of Aug. 1, 2003.9. Abbokinase(R) (urokinase) Contract between St. John’s Health System and Abbott Laboratories Inc. dated as of Oct. 22, 2002.10. Abbokinase(R) (urokinase) Contract between St. John’s Hospital and Abbott Laboratories Inc. dated as of March 1, 2003.11. Abbokinase(R) (urokinase) Contract between St. Joseph’s Medical Center and Abbott Laboratories Inc. dated as of Oct. 15, 2003.12. Abbokinase(R) (urokinase) Contract between St. Mary’s Medical Center and Abbott Laboratories Inc. dated as of July 1, 2003.13. Abbokinase(R) (urokinase) Contract between St. Vincent Infirmary and Abbott Laboratories Inc. dated as of May 29, 2003.14. Vendor Agreement between Abbott Laboratories Inc. and MedAssets HSCA, Inc., dated as of September 3, 2002, as amended.15. Contract between University of Michigan Health System and Abbott Laboratories Inc. dated as of Oct. 1, 2004.16. Contract between Abbott Laboratories Inc., Pharmaceutical Products Division, and the State of Minnesota, Commissioner of Administration (on behalf of the Minnesota Multistate Contracting Alliance for Pharmacy), dated as of June 2, 2004.17. Pharmacy Supplier Agreement between Abbott Laboratories Inc. and Novation, LLC, dated as of March 13, 2001, as amended. *18. Pharmaceutical Purchasing Agreement (PACT) between Abbott Laboratories Inc. and Purchasing Alliance for Clinical Therapeutics, dated as of April 1, 2004. *19. Group Purchasing Agreement between Abbott Laboratories Inc. and Premier Purchasing Partners, L.P., dated as of July 1, 1998, as amended. *20. Corporate Strategic Agreement between Abbott Laboratories Inc. and Johns Hopkins Health System Corporation, dated as of June 1, 2002.21. Abbokinase(R) (urokinase) Contract between HC Pharmacy and Abbott Laboratories Inc. dated as of May 1, 2003.22. Network Agreement between Abbott Laboratories and Kaiser Permanente Medical Care Program, dated March 16, 2006 and effective April 1, 2006. ** INDICATES A “TOP FIVE” MIXED GPO CONTRACT FOR PURPOSES OF SECTION 2.5 SCHEDULE 5.4 – TITLENone. SCHEDULE 5.5 – INTELLECTUAL PROPERTYNone. SCHEDULE 5.6 – LITIGATIONNone. SCHEDULE 5.7 – SELLER CONSENTS1. Abbokinase Fill and Finish Agreement between Hospira, Inc. and Abbott Laboratories, dated April 16, 2004.2. Notification to the FDA of the transfer of NDA 76-1021 will be required. SCHEDULE 5.9 – FINANCIAL DATA ABBOKINASE SALES DATA Wholesaler Reports IMS Data a) To Abbott b) ———————————– ———— Dollars Units Units —————– ————- ————Qtr 1, 2005 $ 6,422,215 17,058 15,579Qtr 2, 2005 $ 5,066,668 13,426 11,555Qtr 3, 2005 $ 3,871,022 10,323 10,742Qtr 4, 2005 $ 3,745,832 9,808 10,275 ———– ——- ——-Total Year 2005 $19,105,737 50,615 48,151 =========== ======= =======Monthly DataOctober, 2005 $ 1,162,662 3,044 3,166November, 2005 $ 1,181,214 3,087 3,329December, 2005 $ 1,401,956 3,677 3,780January, 2006 $ 1,224,207 2,992 3,414February, 2006 $ 1,097,515 2,718 3,577a) Source: IMS Dataviewb) Reflects sales units reported by the top 3 wholesalers (Cardinal, McKesson, and ABC). SCHEDULE 5.12 – GOVERNMENTAL AUTHORIZATIONSNone. SCHEDULE 6.3 – BUYER CONSENTS1. Approval of the board of directors of ImaRx Therapeutics, Inc.2. Notification to the FDA of the transfer of NDA 76-1021 will be required. SCHEDULE 6.8 – INDEBTEDNESS1. Claim for patent reimbursement by Bracco Diagnostics, Inc. against ImaRx Therapeutics, Inc. in the amount of $218,856.2. Secured Promissory Note made by ImaRx Therapeutics, Inc. in favor of Abbott Laboratories, dated as of September 30, 2005 in the initial principal amount of $15,000,000, plus accrued interest thereon. EXHIBIT A BILL OF SALE, CONVEYANCE AND ASSIGNMENT THIS BILL OF SALE, CONVEYANCE AND ASSIGNMENT (this “Instrument”) dated asof April 14, 2006, is made by and between Abbott Laboratories, a corporationorganized and existing under the laws of the State of Illinois and having aprincipal place of business at Abbott Park, Illinois 60064 (herein referred toas “Seller”) and ImaRx Therapeutics, Inc., a corporation organized and existingunder the laws of Delaware and having a principal place of business at 1635 East18th Street, Tucson, Arizona 85719 (herein referred to as “Buyer”) and isdelivered pursuant to, and subject to the terms of, that certain Asset PurchaseAgreement, dated as of April 10, 2006 (the “Asset Purchase Agreement”), by andbetween Seller and Buyer. The terms of the Asset Purchase Agreement are incorporated herein byreference, and capitalized terms not otherwise defined in this Instrument shallhave the meanings given to such terms in the Asset Purchase Agreement. NOW, THEREFORE, subject to the terms and conditions of the Asset PurchaseAgreement and for the consideration set forth therein, Buyer and Seller eachhereby agrees as follows: 1. Seller does hereby sell, convey, transfer, assign and deliver to Buyer,all of its right, title and interest in the Purchased Assets. 2. Notwithstanding anything to the contrary in this Instrument, the AssetPurchase Agreement or in any other document delivered in connection herewith ortherewith, the Purchased Assets subject to this Instrument shall expresslyexclude the Excluded Assets. 3. From time to time, as and when reasonably requested by Buyer, Sellershall execute and deliver all such documents and instruments and shall take, orcause to be taken, all such further or other actions as Buyer may reasonablydeem necessary or desirable to more effectively sell, transfer, convey andassign to Buyer all of Seller’s right, title and interest in the PurchasedAssets subject to this Instrument. 4. This Instrument shall be governed by and construed in accordance withthe internal laws of the State of Illinois applicable to agreements made and tobe performed entirely within such State, without regard to the conflicts of lawsprinciples of such State. 5. To the extent that any provision of this Instrument is inconsistent orconflicts with the Asset Purchase Agreement, the provisions of the AssetPurchase Agreement shall control. * * * * * * * * * * * * * * * IN WITNESS WHEREOF, this Instrument is duly executed and delivered as ofthe date and year first above written. ABBOTT LABORATORIES By: /s/ Sean E. Murphy —————————————— Name: Sean E. Murphy Title: Vice President, Global Licensing/ New Business Development IMARX THERAPEUTICS, INC. By: /s/ Evan C. Unger ——————————————- Name: Evan C. Unger Title: President and Chief Executive Officer EXHIBIT B INTELLECTUAL PROPERTY TRANSFER AGREEMENT This INTELLECTUAL PROPERTY TRANSFER AGREEMENT dated as of April 14,2006 made by Abbott Laboratories, a corporation organized and existing under thelaws of the State of Illinois and having a principal place of business at AbbottPark, Illinois 60064 (herein referred to as “Assignor”) in favor of ImaRxTherapeutics, Inc., a corporation organized and existing under the laws ofDelaware and having a principal place of business at 1635 East 18th Street,Tucson, Arizona 85719 (herein referred to as “Assignee”). WHEREAS, Assignor has rights to the patent applications and issuedpatents listed on Schedule 1 attached hereto (the “Patents”); WHEREAS, Assignee desires to acquire Assignor’s rights in thePatents; For good and valuable consideration, the receipt and sufficiency ofwhich is hereby acknowledged, Assignor hereby transfers, assigns, and otherwiseconveys to Assignee, all of Assignor’s right, title, and interest in, to, andunder the following, subject to the limitations described below: 1. the Patents, including, without limitation, any continuations, divisions, continuations-in-part, reissues, reexaminations, extensions or foreign equivalents thereof, and including the subject matter of all claims that may be obtained therefrom, and all other corresponding rights that are or may be secured under the laws of the United States or any other jurisdiction, now or hereafter in effect; and 2. all proceeds of the assets transferred pursuant to paragraph (1) (collectively, the “Transferred IP”), including, without limitation, the right to sue for, and collect on, (i) any claim by Assignor against third parties for past, present, or future infringement of the Patents, and (ii) any income, royalties or payments due or payable and related exclusively to the Transferred IP as of the date of this assignment or thereafter. Assignor hereby permits the Commissioner of Patents and Trademarksto record Assignee as the assignee and owner of the Patents and Assignor herebyconsents to such recordation. * * * * * * EXHIBIT B Assignor has caused this Intellectual Property Transfer Agreement to beduly executed and authorized as of the date hereof. ABBOTT LABORATORIES By: /s/ Sean E. Murphy —————————————– Name: Sean E. Murphy Title: Vice President, Global Licensing/ New Business Development IMARX THERAPEUTICS, INC. By: /s/ Evan C. Unger —————————————– Name: Evan C. Unger Title: President and Chief Executive Officer EXHIBIT B SCHEDULE 1 PATENTSU.S. Patent No. 5,260,872 issued November 9, 1993, entitled Automated TestingSystem. Exhibit CPreviously Filed as Exhibit no. 10.17 to Registration Statement on Form S-1filed on May 19, 2006 Exhibit DPreviously Filed as Exhibit No. 10.19 to Registration Statement on Form S-1filed on May 19, 2006 Exhibit EPreviously filed as Exhibit No. 10.18 to Registration Statement on Form S-1filed on May 19, 2006 Exhibit FPreviously Filed as Exhibit No. 10.16 to Registration Statement on Form S-1filed on May 19, 2006